Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
CDSCO to fast-track trials and approval for COVID19 vaccine
Arch Pharma Labs has filed the application
The govt has rolled out three schemes for promoting the manufacture of API
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Price band in the range of Rs 933 to Rs 954
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
Subscribe To Our Newsletter & Stay Updated
